Pfizer Inc. ($PFE) Stock Forecast: Down 5.1% Today

What is Pfizer Inc.?

Pfizer Inc. (PFE) is a multinational pharmaceutical corporation known for its wide range of healthcare products. The company is a key player in the pharmaceutical industry, with a focus on developing innovative treatments and vaccines.

Why is Pfizer Inc. going down?

PFE stock is down 5.1% on Dec 16, 2025 18:40

• The bearish movement in Pfizer's stock today could be attributed to profit-taking by investors after a recent bullish run or concerns about competition in the pharmaceutical sector.
• The call-put ratio for Cintas Corp. (CTAS) and the positive outlook on Microsoft Corporation (MSFT) and Regeneron Pharmaceuticals, Inc. (REGN) might have diverted investor attention away from Pfizer.
• Institutional accumulation in Sealed Air Corporation (SEE) and AbbVie Inc. (ABBV) could have signaled more attractive investment opportunities compared to Pfizer, leading to the bearish movement in its stock.
• Overall, Pfizer's bearish movement today may be a short-term market correction influenced by broader market trends and investor sentiment towards other pharmaceutical companies.

PFE Price Chart

PFE Technical Analysis

PFE News

Cintas Corp. (CTAS) call put ratio 3.9 calls to 1 put into quarter results

Cintas Corp. (CTAS) is showing a call-put ratio of 3.9 calls to 1 put leading up to its quarterly results, expected before the bell on December 18. The December call option implied volatility is 77, and January is 33, compared to its 52-week range of 17 to 40. The current analyst rating for CTAS is "SELL," with a dividend yield of 0.8% and revenue growth of 8.2%.

https://www.streetinsider.com/Option+EPS+Action/Cintas+Corp.+%28CTAS%29+call+put+ratio+3.9+calls+to+1+put+into+quarter+results/25745593.html

V. M. Manning & CO. Inc. Buys New Shares in Microsoft Corporation $MSFT

V. M. Manning & CO. Inc. initiated a new position in Microsoft Corporation, purchasing 2,477 shares valued at approximately $1,258,000, making it their 14th largest holding. Wall Street analysts generally maintain a positive outlook on Microsoft, with a "Moderate Buy" rating and a consensus price target of $631.03. Microsoft recently exceeded earnings expectations and announced a quarterly dividend of $0.91 per share.

https://www.marketbeat.com/instant-alerts/filing-v-m-manning-co-inc-buys-new-shares-in-microsoft-corporation-msft-2025-12-16/

Westwood Holdings Group Inc. Grows Position in Regeneron Pharmaceuticals, Inc. $REGN

Westwood Holdings Group Inc. increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.0% in Q2, acquiring an additional 1,974 shares to own a total of 13,556 shares valued at $7.12 million. This move is part of a broader trend of institutional accumulation, with institutions now holding approximately 83.31% of the stock. Regeneron Pharmaceuticals has also received multiple analyst upgrades, leading to a "Moderate Buy" consensus rating and an average price target of $779.45.

https://www.marketbeat.com/instant-alerts/filing-westwood-holdings-group-inc-grows-position-in-regeneron-pharmaceuticals-inc-regn-2025-12-16/

Luminus Management LLC Has $17.65 Million Holdings in Sealed Air Corporation $SEE

Luminus Management LLC significantly increased its stake in Sealed Air Corporation (NYSE:SEE) by 15.1% in the third quarter, bringing their total holdings to 499,161 shares valued at approximately $17.65 million. This makes Sealed Air the third-largest holding and 15.9% of Luminus’s portfolio. The company has a "Moderate Buy" consensus rating from analysts, with a $42.83 average price target, following strong Q3 earnings and a declared quarterly dividend of $0.20 per share.

https://www.marketbeat.com/instant-alerts/filing-luminus-management-llc-has-1765-million-holdings-in-sealed-air-corporation-see-2025-12-16/

32,205 Shares in AbbVie Inc. $ABBV Purchased by Shorepoint Capital Partners LLC

Shorepoint Capital Partners LLC recently acquired 32,205 shares of AbbVie Inc. (ABBV), valued at approximately $7.46 million, making it their 19th largest holding and representing 1.5% of their investment portfolio. This purchase comes as institutional ownership in AbbVie reaches 70.2%, with analysts maintaining a "Moderate Buy" consensus rating and a mean price target of $244.55 following strong Q3 earnings and a dividend increase.

https://www.marketbeat.com/instant-alerts/filing-32205-shares-in-abbvie-inc-abbv-purchased-by-shorepoint-capital-partners-llc-2025-12-16/

Trending Today

Solana ($SOL) Crypto Forecast: Down 5.0% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Down 6.9% Today

SoFi Technologies Inc. ($SOFI) Stock Forecast: Down 5.2% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Down 5.3% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 5.3% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.1% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 8.1% Today

Devon Energy Corporation ($DVN) Stock Forecast: Up 5.2% Today

Western Digital Corporation ($WDC) Stock Forecast: Down 5.0% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 5.3% Today

Pfizer Inc. Price History

30.09.2025 - PFE Stock was up 0.5%

• Despite the bearish options activity detected by investors, Pfizer's stock saw a significant bullish movement, indicating a potential divergence between options trading sentiment and actual market performance.
• Criticism of Plug Power and positive outlook on Sempra did not directly impact Pfizer's bullish movement, suggesting that company-specific news may not have been the primary driver of today's market activity.
• The -1.09% drop in Pfizer's stock price in the latest trading session may have been overshadowed by broader market gains, leading to the overall bullish movement observed.
• With Pfizer's Q3 earnings expected to decline, the market's bullish response today could be attributed to other factors such as positive industry developments or investor sentiment shifting towards pharmaceutical stocks in general.

05.07.2025 - PFE Stock was up 5.0%

• Strong bullish movement attributed to impressive Q2 earnings, beating estimates with significant growth in earnings and revenues.
• Rising sales in oncology drugs like Vyndaqel, Comirnaty, and Paxlovid, as well as cost-cutting measures expected to save billions by 2027, fueled the positive market response.
• Optimism further boosted by the company's raised 2025 EPS guidance and expectations of continued strength in key products like Vyndaqel and Padcev.
• President Trump's ultimatum to lower drug prices may have influenced the overall positive sentiment, potentially benefiting companies like Pfizer in the long run.

05.07.2025 - PFE Stock was up 5.3%

• Pfizer reported better-than-expected Q2 earnings, with EPS beating consensus and sales rising by 10% year-over-year, driven by key products like Vyndaqel, Comirnaty, and Paxlovid.
• The company raised its 2025 EPS guidance and announced cost-cutting measures expected to save $7.7 billion by the end of 2027, which boosted investor confidence in the stock.
• Despite facing declines in some products like Eliquis, Ibrance, and Prevnar, Pfizer's overall performance and future outlook seem promising, leading to the bullish market movement.
• The negative news about Trump issuing an ultimatum to pharmaceutical companies to lower drug prices did not significantly impact Pfizer's stock, as the positive earnings report overshadowed external pressures.

30.08.2025 - PFE Stock was up 5.7%

• Pfizer's stock saw a surge following reports of an agreement with President Trump to lower drug prices voluntarily, showcasing a positive impact on the company's reputation and potential market growth.
• Despite legal challenges related to Depo-Provera brain tumor claims, the news did not notably affect the stock's performance today, with investors focusing on the favorable developments.
• The acquisition of Metsera by Pfizer for next-generation weight loss drugs is viewed as a strategic maneuver that could enhance innovation and research expenditure, bolstering the optimistic sentiment.
• Despite a recent stock price decline, today's bullish movement demonstrates resilience and investor confidence in Pfizer's future prospects, especially with the spotlight on a potential drug-pricing arrangement.

04.10.2025 - PFE Stock was up 0.2%

• Pfizer's stock showed strong bullish movement today after surpassing earnings and revenue estimates for the third quarter of 2025, displaying robust financial performance.
• The market responded positively to Pfizer increasing its profit guidance despite a slight decline in sales, reflecting investor confidence in the company's ability to overcome obstacles and sustain profitability.
• The updated proposal from Novo Nordisk to acquire Metsera might have influenced market sentiment, potentially bolstering Pfizer's position in the pharmaceutical sector as competitors seek strategic acquisitions.
• Overall, Pfizer's strong performance in core drug sales and positive profit outlook in a challenging market environment likely contributed to the bullish movement in its stock price today.

16.11.2025 - PFE Stock was down 5.1%

• The bearish movement in Pfizer's stock today could be attributed to profit-taking by investors after a recent bullish run or concerns about competition in the pharmaceutical sector.
• The call-put ratio for Cintas Corp. (CTAS) and the positive outlook on Microsoft Corporation (MSFT) and Regeneron Pharmaceuticals, Inc. (REGN) might have diverted investor attention away from Pfizer.
• Institutional accumulation in Sealed Air Corporation (SEE) and AbbVie Inc. (ABBV) could have signaled more attractive investment opportunities compared to Pfizer, leading to the bearish movement in its stock.
• Overall, Pfizer's bearish movement today may be a short-term market correction influenced by broader market trends and investor sentiment towards other pharmaceutical companies.

16.11.2025 - PFE Stock was down 4.4%

• Pfizer's bearish movement today is linked to the company's projection of lower profits in 2026 due to an expected decrease in COVID product sales and revenue loss from drugs losing exclusivity. This information likely sparked concerns among investors regarding the company's future earnings.
• Despite confirming its 2025 earnings guidance, Pfizer's updated revenue forecast slightly below Street expectations potentially let down investors, resulting in a sell-off of the stock.
• The institutional accumulation trend in other pharmaceutical companies like Regeneron Pharmaceuticals and AbbVie, accompanied by analyst upgrades and positive earnings, may have diverted investor focus from Pfizer, contributing to the downward movement in its stock price today.
• Shorepoint Capital Partners LLC's investment in Pfizer, coupled with adjustments in holdings by other institutional investors, demonstrates sustained interest in the company despite the profit projection and revenue worries, hinting at a possible stock rebound in the future.

10.10.2025 - PFE Stock was down 2.2%

• The bearish movement in Pfizer's stock could be attributed to the uncertainty surrounding the fierce bidding war with Novo Nordisk over the acquisition of Metsera, Inc., a significant deal worth $10 billion. The market might be reacting negatively to the potential financial implications and risks associated with this high-stakes competition.
• Additionally, Trump's Most Favored Nation (MFN) policy aimed at reducing U.S. drug prices could be adding pressure on Pfizer and other pharmaceutical companies, leading to concerns about future revenue streams and profitability.
• The court's decision to deny Pfizer's request for a temporary restraining order to block Novo Nordisk's bid for Metsera might have further fueled investor uncertainty and contributed to the bearish sentiment surrounding Pfizer's stock.
• Overall, the combination of the bidding war, drug pricing concerns, and legal setbacks could have collectively influenced the bearish market movement for Pfizer today. Investors are likely closely monitoring the developments in these ongoing battles and policy changes to assess the company's future performance.

01.09.2025 - PFE Stock was up 7.7%

• The stock of Pfizer witnessed a significant surge in the market today.
• An agreement on drug pricing with President Donald Trump has fueled this bullish movement, indicating promising prospects for the company's future revenue and competitive position.
• Investor confidence in Pfizer received a boost from this agreement, which also eased industry concerns regarding potential tariff impacts, resulting in a positive market trend.
• Positive remarks from Mark Cuban regarding Trump's online pharmacy initiative and its potential enhancements may have contributed to the optimistic outlook on Pfizer's stock.
• The collaboration between Pfizer and the U.S. government to lower drug prices has not only enhanced the company's stock performance but has also underscored its dedication to addressing healthcare affordability challenges.

01.09.2025 - PFE Stock was up 7.4%

• Pfizer's stock experienced a bullish movement following reports of an agreement with President Donald Trump to lower drug prices. This news likely boosted investor confidence in the company's future prospects.
• The deal with Trump and the positive response from the pharmaceutical industry regarding Pfizer's tariff situation provided a favorable outlook for the company, leading to increased buying interest in the stock.
• Mark Cuban's assessment of Trump's online drug store venture and the upcoming court hearing over Depo-Provera brain tumor claims may have added some volatility to Pfizer's stock but did not deter the overall bullish sentiment driven by the drug pricing deal announcement.
• Overall, the market movement of Pfizer today can be attributed to a combination of positive news related to drug pricing agreements and potential challenges the company may face in the legal arena.

01.09.2025 - PFE Stock was up 7.5%

• Pfizer's stock surged due to a significant agreement with the administration to reduce prescription drug prices, fostering optimism in the pharmaceutical sector.
• Granting Pfizer a three-year exemption from pharmaceutical tariffs by the administration enabled the company to provide medications at reduced prices, bolstering investor confidence.
• The agreement not only benefited Pfizer but also had broader implications for companies such as CVS Health, Eli Lilly, and UnitedHealth Group.
• Market response indicates that Pfizer's strategic decisions and alignment with government policies have positioned it favorably, leading to a bullish trend in its stock price.

25.07.2025 - PFE Stock was down 2.1%

• Pfizer's (PFE) stock price sharply declined today, despite a recent uptrend in the past month, potentially indicating profit-taking or shifting market sentiment.
• Despite reports of major investors taking bullish positions on Pfizer, the market movement appeared bearish today. It's crucial to recognize that multiple factors beyond investor sentiment can influence market dynamics.
• The bearish trend could be linked to overall market movements, industry-specific updates, or internal developments impacting Pfizer's stock negatively.
• Investors are advised to monitor forthcoming announcements or updates regarding Pfizer to gain insights into the causes behind today's market downturn.